Browse: Authors | Keywords | All Center-Authored Publications
Filter by Division: Basic | Clinical | Human Biology | PHS | VIDD (2010-present) | VIDI (2008-2009)
Filter by Year: 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014
Filters: Author is Higano, Celestia S [Clear All Filters]
Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2014.
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.. The New England journal of medicine.. 2014.
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(11):3520-6.. 2011.
Androgen deprivation for prostate cancer.. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2013:176-83.. 2013.
Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014.
Intermittent versus continuous androgen deprivation therapy.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):727-33.. 2014.
Sipuleucel-T.. Nature reviews. Drug discovery. 9(7):513-4.. 2010.
Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(30):3720-5.. 2012.
New treatment options for patients with metastatic castration-resistant prostate cancer.. Cancer treatment reviews. 38(5):340-5.. 2012.
New developments in the treatment of castration-resistant prostate cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5 Suppl):773-6.. 2014.
To Treat or Not to Treat, That Is the Question: The Role of Bone-Targeted Therapy in Metastatic Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014.
Potential use of custirsen to treat prostate cancer.. OncoTargets and therapy. 6:785-97.. 2013.
New and emerging agents for the treatment of castration-resistant prostate cancer.. Urologic oncology. 29(6 Suppl):S1-8.. 2011.
Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.. Journal of molecular cell biology. 4(3):127-32.. 2012.
Intermittent versus continuous androgen deprivation in prostate cancer.. The New England journal of medicine. 368(14):1314-25.. 2013.
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6.. 2009.
Integration of immunotherapy into the management of advanced prostate cancer.. Urologic oncology. 30(5 Suppl):S41-7.. 2012.
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.. The Journal of clinical investigation. 123(10):4410-22.. 2013.
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells.. Digestive diseases and sciences. 55(5):1396-405.. 2010.
Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer.. Current oncology reports. 15(2):69-75.. 2013.
Doing Business with Arnold Library
Weintraub Building, B1-010
More About Arnold Library
- Information for Grant Writers
- Arnold Library News
- Affiliations and Memberships
- Journals List
- Web of Science - Science Citation Index
- Pubmed (Get Article Enabled)
- Library Catalog
- Document Delivery Form
- Center-Authored Papers
- Institutional Repository
- Researcher Profiles